Vivo Bio Tech Ltd

Warrant expiry details

• 6,27,409 convertible equity warrants expired due to non-exercise.
• Out of 25,00,000 warrants issued on Feb 24, 2025 to Dwight Technologies Private Limited.
• Warrants issued at Rs 45 per unit (face value Rs 10, premium Rs 35).
• Expiry occurred within the 18-month tenure from allotment, ending Aug 24, 2026.
• Disclosure made under SEBI LODR Regulation 30 for the regulatory filing.

Key details

• Target: Vivo Bio Tech Limited.
• Disclosing party: M/s Maxcell Communication India Private Limited (Promoter Group).
• Transaction type: Off-market transfer of 12,00,000 equity shares.
• Pre-transaction holding: 12,00,000 shares, 5.41% voting rights.
• Post-transaction holding: 12,00,000 shares, 5.41% voting rights (4.09% diluted).
• Date of transaction: August 21, 2026.
• Intimation receipt: August 22, 2026.
• Equity share capital before/after: 2,21,90,628 shares; diluted capital: 2,93,23,111.

Transaction details

• Target Company: Vivo Bio Tech Limited.
• Disclosing Party: Dwight Technologies Private Limited (non-promoter).
• Transaction Type: Acquisition of 12,00,000 equity shares.
• Pre-Transaction Holding: 18,72,561 shares, 8.44% voting, 6.39% diluted.
• Mode: Off-market acquisition.
• Date of Acquisition: August 22, 2026.
• Post-Transaction Holding: 30,72,561 shares, 13.85% voting, 10.48% diluted.
• Equity share capital before: 2,21,90,628 shares (Rs 22,19,06,280).
• Total diluted share capital after: 2,93,23,111 shares (Rs 29,32,31,110).

Key details

• Target Company: Vivo Bio Tech Limited.
• Disclosing Party: M/s. P.K.L Solution Private Limited (Promoter Group).
• Transaction Type: Transfer of 600,000 equity shares.
• Pre-Transaction Holding: 600,000 voting shares, 2.70% voting rights, 2.05% diluted.
• Transaction Details: 600,000 shares transferred on August 21, 2026.
• Post-Transaction Holding: 2,93,23,111 diluted equity shares (Rs 29,32,31,110).
• Date of Transaction: August 21, 2026; intimation on August 22, 2026.
• Share Capital Context (before): Rs 22,19,06,280; 2,21,90,628 shares.
• Share Capital Context (after): Rs 29,32,31,110; 2,93,23,111 shares.

Mangipudi – WTD re-appointment

• Change: Re-appointment of Kalyan Ram Mangipudi as Whole-Time Director.
• Effective date/term: Aug 22, 2026; Nov 3, 2026–Nov 2, 2031.
• Reason: Retires by rotation and eligible for re-appointment.
• Profile: 25+ years in accounting, finance and administration.
• Shareholders' approval: required.
• Relationships: Not Applicable.
• Board/committee impact: Not specified.

Kompella – WTD re-appointment

• Change: Re-appointment of Sri Kalyan Kompella as Whole-Time Director.
• Appointed Aug 22, 2026; term Nov 3, 2026–Nov 2, 2031.
• Reason: NRC-recommended re-appointment.
• Profile: 25+ years in accounting, finance and administration.
• Shareholders' approval: subject to members' approval.
• Relationships: Not Applicable.

Alangudi – WTD re-appointment

• Change: Re-appointment of Dr. Sankaranarayanan Alangudi as Whole-Time Director.
• Appointed Aug 22, 2026; term Jan 6, 2027–Jan 5, 2032.
• Reason: NRC-recommended re-appointment.
• Profile: Discovery biologist; 45+ years in pharma R&D; GxP expertise.
• Shareholders' approval: subject to members' approval.
• Relationships: Not Applicable.

Promoter warrants expiry

• Total warrants issued: 12,00,000 at Rs 45 each, issued Feb 21, 2025.
• 8,10,000 warrants expired due to non-exercise within 18 months.
• Expired by promoter allottees: Lopa Mudra 3,50,000; Modini 4,60,000.
• Remaining outstanding warrants: 3,90,000 still exercisable.
• Expiry date linked to 18-month tenure: August 21, 2026.
• Regulatory reference: Regulation 162 SEBI ICDR 2018.

Expiry of warrants

• 483 of 2,600,000 warrants expired due to non-exercise.
• Warrants issued on February 20, 2025 at Rs 45 per warrant.
• Allotted on a preferential basis to Antique Infotech Private Limited.
• Expiry date: August 20, 2026, tenure of 18 months.
• No cash inflow from expiry; the warrants expired unexercised.

Resolutions and outcomes

• Re-appointment of Kalyan Ram Mangipudi as Whole-time Director (Ordinary); approved with 99.95% in favour.
• RPT: Madhavi Kompella as Advisor (Strategy & BD) for 5 years; approved 99.55% in favour.
• Material RPT with Virinchi Limited; approved 99.95% in favour.

Key outcomes

• Approved unaudited standalone and consolidated results for Q1 ended 30 June 2026.
• Limited Review Reports by P. Murali & Co; no material misstatement.
• Results prepared under Ind AS; SEBI LODR Regulation 33 compliance noted.